Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Finance and funding news

Show

From To
Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

Published
10 April 2014
From
Inter Press Service
HIV's Grip on the American South

One of the strangest things about the H.I.V. epidemic in the Deep South—from Louisiana to Alabama to Mississippi—is how easily most Americans have elided it, choosing instead to imagine that the disease is now an out-there, elsewhere epidemic.

Published
10 April 2014
From
The New Yorker
Gilead Sciences: How serious is the pricing problem?

There really isn’t much precedent at all for branded companies competing on price in a MAJOR (~double digit) way. Plenty of companies play around with rebates and discounts, but it’s rare that the net price difference between major brands is more than a few percentage points.

Published
09 April 2014
From
Barron's
Express Scripts Raises Pressure on Gilead for Drug Price

Express Scripts Holding Co. (ESRX), a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. (GILD) to cut the $84,000 price of its new hepatitis C pill Sovaldi.

Published
08 April 2014
From
Bloomberg
Briefing: Punitive aid cuts disrupts healthcare in Uganda

Since the enactment of a draconian anti-homosexuality bill in Uganda just over a month ago, donors have been slashing or suspending aid to the country in protest. Health officials, activists and NGOs warn that this could have a major impact on healthcare services, particularly for HIV/AIDS patients.

Published
08 April 2014
From
IRIN
Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser Permanente

Kaiser Permanente, the biggest U.S. health maintenance organization, said it is using Gilead Sciences' new hepatitis C drug, Sovaldi, even though its $84,000 treatment price is "outrageous."

Published
03 April 2014
From
Reuters
International HIV as Prevention Workshop: Day 1 summary

This year’s International HIV Treatment as Prevention Workshop began with an opening roundtable session that gathered high-level delegates from across the globe. The goal of the panel: to bring together the key national decision-makers and pivotal international partners to explore the importance of new HIV treatment targets.

Published
02 April 2014
From
Treatment as Prevention Workshop
How ACA affects vulnerable Americans living with HIV/AIDS

A series of papers recently published examines how the Affordable Care Act could affect two sectors of the most vulnerable Americans -- those living with HIV/AIDS and people who have recently cycled through jail.

Published
02 April 2014
From
Science Daily
HIV Testing Counselor Sells 'Truvada Whore' Shirts For AIDS Charity

Adam Zebowski, an HIV test counselor at the San Francisco AIDS Foundation, is selling #TruvadaWhore t-shirts at a Kickstarter-style site to help meet his AIDS/Lifecycle fundraising goal of $3000.

Published
01 April 2014
From
Towelroad (blog)
Gilead says has discounted hepatitis C drug for some health plans

Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

Published
31 March 2014
From
Reuters
← First12345...65Next →

Filter by country